STUDY OF MUTATION-TARGETED THERAPY WITH SUNITINIB OR EVEROLIMUS IN PEOPLE WITH ADVANCED LOW- OR INTERMEDIATE-GRADE NEUROENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT AND PANCREAS WITH OR WITHOUT CYTOREDUCTIVE SURGERY: